XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Inclusion Criteria: * Provision of signed and dated informed consent form; * Aged 18 to 75 years old; * Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma; * Completed an R0 or R1 surgical resection as determined by pathology； * Have not received any prior neoadjuvant therapy; * ECOG score is 0 or 1; * Life expectancy of greater than 12 months; * CA19-9 \<100U/mL before initial chemotherapy; * Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug. * Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol. Exclusion Criteria: * Borderline resectable pancreatic cancer; * Evidence of disease recurrence or metastasis following surgical resection at any time; * Evidence of malignant ascites; * Pre-existing inflammatory bowel disease or the presence of complete or partial bowel obstruction, or persistent severe diarrhea after surgery; * Needs to receive long-term systemic anti-allergic drug or known hypersensitivity to any component of the study treatment; * History of autoimmune disease; * New cerebrovascular accident (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack) within 6 months before screening; * Acute myocardial infarction within 6 months before screening, or uncontrolled angina, uncontrolled arrhythmia, severe heart failure (see Appendix 3, New York Heart Association Heart Failure Classification Criteria NYHA Class ≥ III) and other cardiovascular diseases; * Received immunomodulatory medications within 4 weeks prior to the date of the first dose (D1) of XH001, including but not limited to: IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, IFN-α; * Received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 7 days prior to the first dose of XH001; * Received therapeutic tumor vaccines; * With congenital or acquired immunodeficiency; * Participating in other clinical trials and had not withdrawn during screening period; * Unable or unwilling to comply with the study protocol due to potential health, mental or social conditions in the opinion of the investigator; * Other conditions that, in the opinion of the investigator, would make participation in this study inappropriate.